CLEAR/CURES Seminar: Dr. Allen J. Wilcox (Nat'l Institute for Env Health Sciences) Oct 9, 2025

Value of the Information & Strength of the Argument

The talk provides a compelling critique of the use of SGA as a proxy for FGR, supported by empirical data from ROC analyses and multiple epidemiological studies. The argument is well-structured, logically sound, and clearly presented. The speaker effectively demonstrates the limitations of current definitions and the need for a paradigm shift. The value of the information is high, as it challenges a widely used practice and offers a path forward.

Scientific Rigor, Source Quality, Title Accuracy

The presentation is based on a published paper and references several studies, including a latent class analysis by Jennifer Hutchinson. The speaker is a leading expert in reproductive epidemiology, and his arguments are grounded in solid methodology. The title accurately reflects the content. The talk is scientifically rigorous, and the sources cited are credible. The adequacy between title and content is excellent.

The title accurately reflects the seminar content, which is a presentation by Dr. Allen J. Wilcox on the study of fetal growth restriction.

9/10

The speaker is a highly respected epidemiologist with extensive experience and publications. The talk is based on a published paper and presents a well-reasoned argument with supporting data. The presentation is clear and acknowledges limitations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction of Dr. Allen J. Wilcox by Stephen.
• 03:00Dr. Wilcox begins his talk, explaining the importance of the topic and the challenge of defining fetal growth restriction.
• 10:00Discussion of the use of SGA as a surrogate marker and its advantages.
• 15:00Presentation of ROC analysis results showing poor predictive value of birth weight percentiles for neonatal mortality.
• 20:00Comparison with gestational age as a predictor, which has an AUC of 88%.
• 25:00Explanation of the conceptual distinction between SGA and FGR, using a Venn diagram.
• 30:00Discussion of false conclusions about prevalence and mortality risk when using SGA.
• 35:00Presentation of latent class analysis study by Jennifer Hutchinson, showing FGR prevalence of ~1% in term births.
• 40:00Comparison of birth weight distribution in FGR vs. unaffected, showing a shift of 1.6 SD.
• 45:00Discussion of converging evidence from multiple studies on FGR prevalence and high relative risk.
• 50:00Call for clinical markers and collaborative research to better define FGR.
• 55:00Q&A session begins.

• On the Study of Fetal Growth Restriction, Time to Abandon SGA — The paper on which this talk is based, published by Dr. Wilcox.
• Predicting adverse perinatal outcomes by various customized and population-based standards for fetal growth — Study from Roberto Romero's group, cited in the talk, showing poor predictive value of fetal size standards.

• Fetal growth restriction: current knowledge — General review supporting the challenges in defining FGR.

• Small for gestational age and risk of long-term adverse outcomes — Some studies may still support the use of SGA as a useful marker for adverse outcomes, though they may not address the distinction from FGR.